Determinants of Response to Neoadjuvant Chemotherapy for Esophageal Cancer Using 18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG-PET)

被引:37
作者
Miyata, Hiroshi [1 ]
Yamasaki, Makoto [1 ]
Takahashi, Tsuyoshi [1 ]
Murakami, Kohei
Tanaka, Koji [1 ,2 ]
Yukinori, Kurokawa [1 ]
Nakajima, Kiyokazu [1 ]
Takiguchi, Shuji [1 ]
Morii, Eiichi [2 ]
Hatazawa, Jun [3 ]
Mori, Masaki [1 ]
Doki, Yuichiro [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka, Japan
[3] Osaka Univ, Grad Sch Med, Dept Nucl Med & Tracer Kinet, Suita, Osaka, Japan
关键词
SQUAMOUS-CELL CARCINOMA; PREOPERATIVE CHEMOTHERAPY; ESOPHAGOGASTRIC JUNCTION; HISTOPATHOLOGIC RESPONSE; METABOLIC-ACTIVITY; SURGICAL THERAPY; CONTROLLED TRIAL; FDG-PET; SURVIVAL; CHEMORADIOTHERAPY;
D O I
10.1245/s10434-013-3343-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. F-18-FDG-PET is potentially useful for evaluating response to neoadjuvant therapy for esophageal cancer. However, the optimal F-18-FDG-PET parameter for evaluating the response to therapy and survival has not been established. This study aimed to select the best of the two parameters of fluorodeoxyglucose (F-18-FDG)-positron emission tomography (PET): decreased ratio of maximal standardized uptake (SUVmax-DR) or absolute value of posttreatment SUVmax (post-SUVmax), in predicting response and survival of patients with esophageal cancer who underwent neoadjuvant chemotherapy. Methods. The study subjects were 211 consecutive patients with esophageal cancer who received neoadjuvant chemotherapy followed by surgery. F-18-FDG-PET was performed before and 2-3 weeks after completion of neoadjuvant chemotherapy in assessment with pretreatment SUVmax (pre-SUVmax), post-SUVmax and SUVmax-DR. Results. The mean SUVmax decreased during neoadjuvant chemotherapy from 11.4 to 5.8, and the mean SUVmax-DR was 49.4 %. Both post-SUVmax and SUVmax-DR correlated significantly with pathological response, although neither post-SUVmax nor SUVmax-DR could distinguish pathological complete response from pathological good response. The 5-year survival rate was significantly higher in patients with SUVmaxDR of >50 % than those with <50 % (56.5 vs. 39.6 %, p = 0.0137), and also significantly higher in patients with post-SUVmax of <3.5 than those with >3.5 (62.2 vs. 35.1 %, p < 0.0001). Multivariate analysis identified post-SUVmax value, but not SUVmax-DR, as an independent prognostic factor in patients who underwent neoadjuvant chemotherapy. Conclusions. Post-SUVmax is more useful for predicting survival of patients with esophageal cancer who undergo neoadjuvant therapy followed by surgery, although both SUVmax-DR and post-SUVmax equally correlate with pathological response.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 38 条
[1]  
Ancona E, 2001, CANCER, V91, P2165, DOI 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO
[2]  
2-H
[3]   A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) [J].
Ando, Nobutoshi ;
Kato, Hoichi ;
Igaki, Hiroyasu ;
Shinoda, Masayuki ;
Ozawa, Soji ;
Shimizu, Hideaki ;
Nakamura, Tsutomu ;
Yabusaki, Hiroshi ;
Aoyama, Norio ;
Kurita, Akira ;
Ikeda, Kenichiro ;
Kanda, Tatsuo ;
Tsujinaka, Toshimasa ;
Nakamura, Kenichi ;
Fukuda, Haruhiko .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :68-74
[4]  
Bancewicz J, 2002, LANCET, V359, P1727
[5]   Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival [J].
Berger, AC ;
Farma, J ;
Scott, WJ ;
Freedman, G ;
Weiner, L ;
Cheng, JD ;
Wang, H ;
Goldberg, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4330-4337
[6]   The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas [J].
Brücher, BLDM ;
Becker, K ;
Lordick, F ;
Fink, U ;
Sarbia, M ;
Stein, H ;
Busch, R ;
Zimmermann, F ;
Molls, M ;
Höfler, H ;
Siewert, JR .
CANCER, 2006, 106 (10) :2119-2127
[7]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[8]   Whole body 18FDG-PET and the response of esophageal cancer to induction therapy:: Results of a prospective trial [J].
Downey, RJ ;
Akhurst, T ;
Ilson, D ;
Ginsberg, R ;
Bains, MS ;
Gonen, M ;
Koong, H ;
Gollub, M ;
Minsky, BD ;
Zakowski, M ;
Turnbull, A ;
Larson, SM ;
Rusch, V .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) :428-432
[9]   Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [J].
Flamen, P ;
Lerut, A ;
Van Cutsem, E ;
De Wever, W ;
Peeters, M ;
Stroobants, S ;
Dupont, P ;
Bormans, G ;
Hiele, M ;
De Leyn, P ;
Van Raemdonck, D ;
Coosemans, W ;
Ectors, N ;
Haustermans, K ;
Mortelmans, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3202-3210
[10]   Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [J].
Gebski, Val ;
Burmeister, Bryan ;
Smithers, B. Mark ;
Foo, Kerwyn ;
Zalcberg, John ;
Simes, John .
LANCET ONCOLOGY, 2007, 8 (03) :226-234